Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report
Leonard Bopp, Meinrad Beer, Stefan Andreas Schmidt, Thomas Seufferlein, Thomas Ettrich, Nuh N Rahbari, Emrullah Birgin · 2026
Read Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report by Leonard Bopp, Meinrad Beer, Stefan Andreas Schmidt, Thomas Seufferlein, Thomas Ettrich, Nuh N Rahbari, Emrullah Birgin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13525799.txt.
Description
Leonard Bopp and co-authors report a liver cancer wiped out by immune drugs before surgery in a 2026 case report. Guides call for drug care alone at this late stage, yet the group of such patients is mixed, which leaves room for plans cut to the case.
The man, aged seventy-two, bore a large tumor that had grown into the liver's main vein on both sides, with a past of hepatitis C. Two immune drugs ran for four months. The tumor shrank in part and the liver held its health. The board then backed a robot two-step cut that took the mass out in two sittings a fortnight apart. The slice read showed no live cancer left. A year on, the man was free of the ill with a sound liver and a better life.
Catalog record
| CREATOR | Leonard Bopp, Meinrad Beer, Stefan Andreas Schmidt, Thomas Seufferlein, Thomas Ettrich, Nuh N Rahbari, Emrullah Birgin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |